Charalambos Andreadis, MD

Conference Coverage

Ibrutinib With Standard Conditioning and as Consolidation Therapy Following AutoHCT Well-Tolerated Among Patients With DLBCL

12/10/2023

Charalambos Andreadis , MD;

At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Charalambos Andreadis, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products